Valuation: Allogene Therapeutics, Inc.

Market Cap 725M 634M 585M 540M 1.02B 69.13B 1.04B 6.99B 2.74B 34.06B 2.72B 2.66B 117B P/E 2026 *
-2.99x
P/E 2027 * -2.8x
Enterprise Value 539M 472M 435M 402M 762M 51.42B 775M 5.2B 2.04B 25.33B 2.02B 1.98B 87.08B EV / Sales 2026 *
89,857x
EV / Sales 2027 * 48.1x
Free-Float
83.53%
Yield 2026 *
-
Yield 2027 * -
1 day-4.52%
1 week-4.31%
Current month-3.85%
1 month+12.36%
3 months-26.47%
6 months+19.76%
Current year+45.99%
1 week 1.94
Extreme 1.94
2.18
1 month 1.75
Extreme 1.75
2.25
Current year 1.31
Extreme 1.31
4.46
1 year 0.98
Extreme 0.9842
4.46
3 years 0.86
Extreme 0.8621
6.05
5 years 0.86
Extreme 0.8621
27.86
10 years 0.86
Extreme 0.8621
55
Manager TitleAgeSince
Chief Executive Officer 48 01/07/2026
Director of Finance/CFO 61 16/10/2023
Chief Tech/Sci/R&D Officer 49 28/02/2025
Director TitleAgeSince
Chairman 76 01/11/2017
Director/Board Member 49 01/11/2017
Director/Board Member 79 01/04/2018
Date Insider Type Main position Quantity % Market Cap.
07-01Free

Chief Executive Officer

610,720 0.1769%
06-18Free

Director

144,400 0.0418%
06-18Free

Director

95,400 0.0276%
Change 5-day change 1-year change 3-year change Capi.($)
-4.52%-4.31%+58.73%-66.44% 725M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-3.23%+3.19%+19.08%+464.22% 25.63B
-1.57%-2.41%-19.53%-14.67% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-0.92%+2.18%+25.61%+197.54% 14.35B
Average -1.16%+1.14%+54.94%+123.91% 24.29B
Weighted average by Cap. -1.14%+0.30%+55.01%+137.23%

Financials

2026 *2027 *
Net sales 6K 5.25K 4.84K 4.47K 8.48K 572K 8.63K 57.84K 22.71K 282K 22.53K 22.04K 969K 12.97M 11.35M 10.47M 9.67M 18.34M 1.24B 18.65M 125M 49.11M 610M 48.71M 47.65M 2.1B
Net income -197M -172M -159M -146M -278M -18.75B -283M -1.89B -744M -9.24B -738M -722M -31.75B -227M -199M -183M -169M -321M -21.66B -327M -2.19B -860M -10.67B -853M -834M -36.69B
Net Debt -186M -162M -150M -138M -263M -17.71B -267M -1.79B -703M -8.72B -697M -682M -29.99B -101M -88.17M -81.32M -75.11M -143M -9.61B -145M -972M -382M -4.74B -378M -370M -16.28B
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Employees
151
Date Price Change Volume
10/07/26 $2.000 -4.76% 6,252,753
09/07/26 $2.100 -0.94% 6,544,217
08/07/26 $2.120 -1.40% 12,427,645
07/07/26 $2.150 +2.87% 14,393,128
06/07/26 $2.090 +0.48% 10,911,873
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
2.100USD
Average target price
8.485USD
Spread / Average Target
+304.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALLO Stock